Sökning: onr:"swepub:oai:DiVA.org:uu-307551" >
Lenalidomide-bendam...
-
Albertsson-Lindblad, AlexandraSkane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.
(författare)
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- Artikel/kapitelEngelska2016
Förlag, utgivningsår, omfång ...
-
American Society of Hematology,2016
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-307551
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-307551URI
-
https://doi.org/10.1182/blood-2016-03-704023DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter, open-label phase 1/2 trial, we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL. Patients >65 years with untreated MCL, stages II-IV were eligible for inclusion. Primary end points were maximally tolerable dose (MTD) of LEN and progression-free survival (PFS). Patients received 6 cycles every four weeks of L-B-R (L D1-14, B 90 mg/m(2) IV, days 1-2 and R 375 mg/m(2) IV, day 1) followed by single LEN (days 1-21, every four weeks, cycles 7-13). Fifty-one patients (median age 71 years) were enrolled from 2009 to 2013. In phase 1, the MTD of LEN was defined as 10 mg in cycles 2 through 6, and omitted in cycle 1. After 6 cycles, the complete remission rate (CRR) was 64%, and 36% were MRD negative. At a median follow-up time of 31 months, median PFS was 42 months and 3-year overall survival was 73%. Infection was the most common nonhematologic grade 3 to 5 event and occurred in 21 (42%) patients. Opportunistic infections occurred in 3 patients: 2 Pneumocystis carinii pneumonia and 1 cytomegalovirus retinitis. Second primary malignancies (SPM) were observed in 8 patients (16%). LEN could safely be combined with R-B when added from the second cycle in patients with MCL, and was associated with a high rate of CR and molecular remission. However, we observed a high degree of severe infections and an unexpected high number of SPMs, which may limit its use. This trial is registered at www.Clinicaltrials.gov as #NCT00963534.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Kolstad, ArneOslo Univ Hosp, Dept Oncol, Oslo, Norway.
(författare)
-
Laurell, AnnaUniv Uppsala Hosp, Dept Oncol, Uppsala, Sweden.(Swepub:uu)annajohn
(författare)
-
Raty, RiikkaHelsinki Univ Hosp, Dept Hematol, Helsinki, Finland.
(författare)
-
Gronbaek, KirstenRigshosp, Dept Hematol, Copenhagen, Denmark.
(författare)
-
Sundberg, JanSkane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.
(författare)
-
Pedersen, Lone BredoRigshosp, Dept Hematol, Copenhagen, Denmark.
(författare)
-
Ralfkiaer, ElisabethRigshosp, Dept Pathol, Copenhagen, Denmark.
(författare)
-
Karjalainen-Lindsberg, Marja-LiisaUniv Helsinki, Cent Hosp, Dept Pathol, Helsinki, Finland.
(författare)
-
Sundström, ChristerUppsala universitet,Klinisk och experimentell patologi,Department of Pathology, Uppsala University Hospital, Uppsala, Sweden; and.,Rose-Marie Amini(Swepub:uu)chrisund
(författare)
-
Ehinger, MatsUniv Lund Hosp, Dept Pathol Cytol, Lund, Sweden.
(författare)
-
Geisler, ChristianRigshosp, Dept Hematol, Copenhagen, Denmark.
(författare)
-
Jerkeman, MatsSkane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.
(författare)
-
Skane Univ Hosp, Dept Oncol, SE-22185 Lund, Sweden.Oslo Univ Hosp, Dept Oncol, Oslo, Norway.
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Blood: American Society of Hematology128:14, s. 1814-18200006-49711528-0020
Internetlänk
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
Albertsson-Lindb ...
-
Kolstad, Arne
-
Laurell, Anna
-
Raty, Riikka
-
Gronbaek, Kirste ...
-
Sundberg, Jan
-
visa fler...
-
Pedersen, Lone B ...
-
Ralfkiaer, Elisa ...
-
Karjalainen-Lind ...
-
Sundström, Chris ...
-
Ehinger, Mats
-
Geisler, Christi ...
-
Jerkeman, Mats
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Klinisk laborato ...
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Uppsala universitet